Skip to main content
NVDA-0.29%AAPL+1.03%GOOGL-2.28%MSFT-0.01%AMZN-0.01%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.70%TSLA-0.62%SKHY+7.05%MU-1.56%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-1.62%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-0.84%0005.HK-0.78%HSBA.L-1.78%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.28%CHFJPY-1.76%USDJPY-1.63%AUDJPY-1.56%EURJPY-1.45%CADJPY-1.45%GBPJPY-1.41%GBPNZD+0.87%EURNZD+0.86%NZDCAD-0.85%AUDNZD+0.75%NZDUSD-0.68%NZDCHF-0.55%GBPTRY+0.41%GBPCHF+0.34%GBPHKD+0.32%EURCHF+0.31%CADCHF+0.30%GBPMXN-0.28%EURZAR+0.26%EURNOK+0.25%USDNOK+0.25%USDZAR+0.24%GBPZAR+0.22%GBPUSD+0.21%AUDCHF+0.21%EURUSD+0.17%USDCAD-0.16%USDILS+0.16%CHFNOK+0.16%USDCHF+0.15%NOKJPY-0.14%NZDSGD+0.14%AUDDKK-0.14%AUDCAD-0.13%GBPAUD+0.12%USDTHB+0.12%AUDNOK+0.11%EURAUD+0.11%USDTRY+0.11%EURSEK+0.10%USDSEK+0.09%EURSGD+0.09%USDSGD+0.09%NZDMXN+0.07%EURCZK-0.07%EURPLN+0.07%AUDUSD+0.07%USDPLN+0.06%GBPSGD+0.06%AUDSGD-0.05%USDMXN+0.04%PLNJPY+0.04%USDCOP-0.04%USDCNH-0.03%SGDJPY+0.02%GBPCAD+0.02%EURGBP-0.02%USDHKD+0.01%CHFSGD-0.01%EURHKD0.00%EURDKK0.00%EURCNH0.00%EURCAD0.00%CHFSEK0.00%USDDKK0.00%COFFEE-2.29%XPTUSD-1.82%SUGAR+1.74%COCOA-1.52%COTTON+1.30%XAGUSD-1.16%GAGUSD-1.16%USOIL+0.81%UKOIL+0.69%HG1-0.58%S1+0.56%C1+0.52%BTCUSD-0.46%ETHUSD-0.08%USDTUSD-0.07%XRPUSD-1.36%SOLUSD-0.68%TRXUSDT+0.39%ZECUSDT-2.20%DOGEUSD-1.46%XMRUSDT-1.03%LINKUSD-0.27%XLMUSD-1.16%BCHUSDT-1.97%LTCUSD-1.80%UNIUSD-2.83%TONUSD+24.88%HBARUSDT-1.34%SUIUSD-1.61%TAOUSDT-1.18%AAVEUSD-1.60%DOTUSDT-2.54%ICPUSDT-1.21%ONDOUSDT-2.17%WLDUSDT-2.19%ATOMUSDT-2.27%ARBUSDT-1.00%JUPUSDT-2.96%INJUSDT-2.53%STXUSDT-3.07%FETUSDT-2.45%TIAUSDT-1.13%SEIUSDT-3.91%PYTHUSDT-1.40%IMXUSDT-2.27%WIFUSDT-3.42%GRTUSDT-2.41%OPUSDT-3.00%POLUSDT-2.75%IOTAUSDT-2.57%AXSUSDT-2.14%FARTCOINUSDT-1.81%EOSUSDT-0.31%DYDXUSDT-0.60%ORDIUSDT+0.34%GALAUSDT-3.65%NOTUSDT-0.68%RONINUSDT-0.71%NVDA-0.29%AAPL+1.03%GOOGL-2.28%MSFT-0.01%AMZN-0.01%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.70%TSLA-0.62%SKHY+7.05%MU-1.56%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-1.62%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-0.84%0005.HK-0.78%HSBA.L-1.78%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.28%CHFJPY-1.76%USDJPY-1.63%AUDJPY-1.56%EURJPY-1.45%CADJPY-1.45%GBPJPY-1.41%GBPNZD+0.87%EURNZD+0.86%NZDCAD-0.85%AUDNZD+0.75%NZDUSD-0.68%NZDCHF-0.55%GBPTRY+0.41%GBPCHF+0.34%GBPHKD+0.32%EURCHF+0.31%CADCHF+0.30%GBPMXN-0.28%EURZAR+0.26%EURNOK+0.25%USDNOK+0.25%USDZAR+0.24%GBPZAR+0.22%GBPUSD+0.21%AUDCHF+0.21%EURUSD+0.17%USDCAD-0.16%USDILS+0.16%CHFNOK+0.16%USDCHF+0.15%NOKJPY-0.14%NZDSGD+0.14%AUDDKK-0.14%AUDCAD-0.13%GBPAUD+0.12%USDTHB+0.12%AUDNOK+0.11%EURAUD+0.11%USDTRY+0.11%EURSEK+0.10%USDSEK+0.09%EURSGD+0.09%USDSGD+0.09%NZDMXN+0.07%EURCZK-0.07%EURPLN+0.07%AUDUSD+0.07%USDPLN+0.06%GBPSGD+0.06%AUDSGD-0.05%USDMXN+0.04%PLNJPY+0.04%USDCOP-0.04%USDCNH-0.03%SGDJPY+0.02%GBPCAD+0.02%EURGBP-0.02%USDHKD+0.01%CHFSGD-0.01%EURHKD0.00%EURDKK0.00%EURCNH0.00%EURCAD0.00%CHFSEK0.00%USDDKK0.00%COFFEE-2.29%XPTUSD-1.82%SUGAR+1.74%COCOA-1.52%COTTON+1.30%XAGUSD-1.16%GAGUSD-1.16%USOIL+0.81%UKOIL+0.69%HG1-0.58%S1+0.56%C1+0.52%BTCUSD-0.46%ETHUSD-0.08%USDTUSD-0.07%XRPUSD-1.36%SOLUSD-0.68%TRXUSDT+0.39%ZECUSDT-2.20%DOGEUSD-1.46%XMRUSDT-1.03%LINKUSD-0.27%XLMUSD-1.16%BCHUSDT-1.97%LTCUSD-1.80%UNIUSD-2.83%TONUSD+24.88%HBARUSDT-1.34%SUIUSD-1.61%TAOUSDT-1.18%AAVEUSD-1.60%DOTUSDT-2.54%ICPUSDT-1.21%ONDOUSDT-2.17%WLDUSDT-2.19%ATOMUSDT-2.27%ARBUSDT-1.00%JUPUSDT-2.96%INJUSDT-2.53%STXUSDT-3.07%FETUSDT-2.45%TIAUSDT-1.13%SEIUSDT-3.91%PYTHUSDT-1.40%IMXUSDT-2.27%WIFUSDT-3.42%GRTUSDT-2.41%OPUSDT-3.00%POLUSDT-2.75%IOTAUSDT-2.57%AXSUSDT-2.14%FARTCOINUSDT-1.81%EOSUSDT-0.31%DYDXUSDT-0.60%ORDIUSDT+0.34%GALAUSDT-3.65%NOTUSDT-0.68%RONINUSDT-0.71%
BP

BioMarin Pharmaceutical Inc. (BMRN)

NASDAQ • Healthcare

$64.41
-$0.21 (-0.3%)
Market closed

Last close at September 9, 2026 at 20:00 UTC

Open$64.06
Day Range$63.64 - $65.33
Avg. Volume (3M)1.8M
Market Cap$12.4B
P/E Ratio169.5
52 Week Range
$49.26$70.98
Next EarningsIn 46 daysOct 26, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$989.7M100%
Gross Profitminus cost of goods$786.9M80%
Operating Incomeminus R&D and overhead$110.9M11%
Net Incomeminus taxes and the rest$44.7M5%

In plain terms: out of every $100 in revenue, BioMarin Pharmaceutical Inc. keeps $5 as net profit.

Fundamentals & Financials

Revenue (TTM)
$3.4B
Net Income (TTM)
$72.9M
EPS (TTM)
$0.38
ROA (TTM)
0.62%
Current Ratio
2.39

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-241.7%Q1 2026-$0.24
-2.6%Q2 2026$0.76
+26.7%Q3 2026$1.2
Next

Oct 26

in 46 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +26.7%

BioMarin Pharmaceutical beat consensus on both revenue and adjusted EPS in the second fiscal quarter of 2026, reported on August 6, as revenue of $989.7 million against a $932.0 million estimate, +6.2%, and adjusted EPS of $1.20 against a $0.95 estimate, +27%. Revenue rose 20% to about $990 million from $825.4 million a year ago, with VOXZOGO leading at $252.5 million, up 14%, while PALYNZIQ climbed 28% to about $135.2 million. Gross margin held near 80% and operating margin was about 11%, while net income fell 81% to about $45 million from $240.5 million a year ago and adjusted EPS of $1.20 was down 2.4% from $1.23. Operating cash flow was about $168 million, and consensus for the next period calls for EPS of $1.38 on revenue of $1.033 billion.

View full earnings history

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for severe rare disorders and other serious medical conditions. Its products serve genetically defined diseases, and the company generated $3.2 billion of revenue in FY2025. BioMarin trades on the NASDAQ under the ticker BMRN.

Name
BioMarin Pharmaceutical Inc.
CEO
Alexander Hardy
Website
www.biomarin.com
Industry
Healthcare
Year Founded
1996
Employees
3,221

Today's Snapshot

AI-generated

BMRN ended the day slightly lower at 64.41, in line with a flat sector. BioMarin announced positive Phase 3 results for VOXZOGO, a growth treatment for children with hypochondroplasia.

Trading Volume

Below 10d avg (1.8M)

1.5M

vs S&P 500 Today

Inline with Market

+0.08%

Updated: September 9, 2026 at 20:14 UTC

Technical Indicators

3 Buy3 Neutral2 Sell
BMRN presents a mixed, neutral technical picture with momentum and oscillator readings hovering near center and the MACD only slightly positive, so there is no clear directional bias. Short-term averages sit marginally above the market while medium- and long-term averages offer support, and the ADX points to weak trend strength, implying limited follow-through either way. Volatility is modest and on-balance volume is subdued, which underlines the lack of conviction. The pivot level is roughly in line with price, reinforcing the balance. Technical takeaway: neutral — short-term softness versus longer-term support with low trend conviction.
All signals
  • EMA (5 indicators)$58.68 - $65.54
    Buy
  • RSI (14)48.04
    Neutral
  • Stochastic %K (14, 3, 3)23.48
    Neutral
  • MACD Level (12, 26)0.61
    Neutral

Peers & Related Assets

MRNAModerna, Inc.
$135.61-3.4%
RVMDRevolution Medicines, Inc.
$207.68+0.2%
BBIOBridgeBio Pharma, Inc.
$76.08+1.8%
EXELExelixis, Inc.
$58.33+1.1%
HALOHalozyme Therapeutics, Inc.
$107.39-0.8%
MDGLMadrigal Pharmaceuticals, Inc.
$546.66+2.3%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.